Independent Grants for Learning & Change (IGLC) Addressing Education in Relation to Tobacco Dependence Treatment in Spain

IMPORTANT: Kindly note, all requests must be submitted in English.

I. Background

The mission of Pfizer Independent Grants for Learning & Change (IGL&C) is to partner with the global healthcare community to improve patient outcomes in areas of mutual interest through support of measurable learning and change strategies. "Independent" means that the projects funded by Pfizer are the full responsibility of the recipient organization. Pfizer has no influence over any aspect of the projects and only asks for reports about the results and the impact of the projects in order to share them publicly.

Through this Call for Grant Applications (CGA) we encourage organizations to submit grant requests that, if funded, will support education in a specific disease state, therapeutic area, or broader area of educational need. Educational activities should not be focused on products specific to Pfizer.

When a CGA is issued, it is posted on the IGL&C website in the <u>Grants Process section</u> and is sent via e-mail to all registered users in our grants system. Some CGAs may also be posted on the websites of other relevant organizations.

II. Eligibility

Geographic Scope:	☑ Spain only
Applicant Eligibility Criteria:	The following may apply: medical, dental, nursing, allied health, and/or pharmacy professional schools; healthcare institutions (both large and small); professional associations and medical societies; medical education companies; and other entities with a mission related to healthcare professional education and/or healthcare improvement.
	More information on organizations eligible to apply directly for a grant can be found at http://www.pfizer.com/files/IGLC OrganizationEligibility effJuly2015.pdf.
	Collaborations within institutions (e.g., between departments and/or interprofessional), as well as between different institutions/organizations/associations, are encouraged. All partners must have a relevant role, and the requesting organization must have a leadership role.

III. Requirements

Date CGA Issued:	3 rd April 2018
Clinical Area:	'
	Smoking Cessation – Tobacco Dependence Treatment Tobacco use is the single most preventable says of death and disease and of sountries in
Specific Area of Interest for this CGA:	Tobacco use is the single most preventable cause of death and disease and, of countries in Europe, Spain still has a high prevalence of tobacco smoking among adults and adolescents (26%) ¹ which is cause for concern. Equally worryingly, this situation is not expected to change substantially in the short-term, due to the observed stabilisation in the number of smokers in Spain in recent years ² .
	In Spain, 166 men and 44 woment die from smoking related diseases each day, and 15% of all deaths in Spain are attributable to tobacco ³ . These deaths could be preventable if appropriate education, support and treatment were utilised in more cases.
	It is our intent to support programs that strive to increase the number of patients who stop smoking by improving the frequency and effectiveness of healthcare professional smoking cessation interventions. This CGA is to encourage academic and healthcare organisations to submit applications focused on educating healthcare professionals on the latest clinical data-driven updates in tobacco dependence treatments.
	Applications focusing on one or more of the following criteria will be given preference:
	- Educating physicians to initiate smoking cessation discussions with patients and to promote the health benefits of smoking cessation
	 Educating physicians about the importance of initiating smoking cessation therapy
	 Increasing physician awareness of the available treatment and support mechanisms required for smoking cessation
	 Educating physicians about the importance of ensuring appropriate follow-up with patients following initiation of smoking cessation treatment/counselling to ensure compliance
	While programing targeted at addressing knowledge gaps may involve live sessions, efforts should be made to encourage interaction and provide opportunities to extend learning opportunities beyond the live setting. In addition to live programs, technology-enabled distance learning with facilitated interactive components, online courses, and other enduring materials may also be proposed.
	More information on principles of learning and behavior change for health professionals can be found at www.pfizer.com/files/HealthProfessionalsLearningandBehaviorChange_AFewPrinciples.p df .
Expected Approximate Monetary Range of Grant Applications:	Individual projects requesting up to \$50,000 USD will be considered. The total available budget related to this CGA is \$150,000 USD.
	The grant amount Pfizer will be prepared to fund will depend upon the evaluation of the proposal and costs involved and will be stated clearly in the approval notification.

Key Dates:	CGA release date: 3 rd April 2018
	Grant application due date: 7 th June 2018
	Please note the deadline is midnight Eastern Time (New York, GMT -5).
	Anticipated Grant Award Notification Date: By the end of July 2018
	Grants distributed following execution of fully signed Letter of Agreement
	Period of Performance of projects: 18 months maximum
	Projects to commence after 1 st September 2018.
How to Submit:	Please go to the specific <u>application log-in page</u> and sign in. First-time users should click "REGISTER NOW".
	Select the following Educational Area: CGA- Spain Tobacco Dependence 2018
	Requirements for submission:
	Complete all required sections of the online application and upload the completed CGA
	template (see Appendix). If you encounter any technical difficulties with the grant management system, please click the "Need Support?" link at the bottom of the page.
	IMPORTANT: Be advised applications submitted through the wrong application type and/or submitted after the due date will not be reviewed by the committee.
Questions:	If you have questions regarding this CGA, please direct them in writing to, Jo Harbron at (jo.harbron@pfizer.com), with the subject line "Spain Tobacco Dependence April 2018".
Mechanism by which Applicants will be	All applicants will be notified via email by the dates noted above.
Notified:	Applicants may be asked for additional clarification or to make a summary presentation during the review period.

References:

- WHO Report on the Global Tobacco Epidemic 2013: Enforcing bans on tobacco advertising, promotion and sponsorship. Available at: http://apps.who.int/iris/bitstream/10665/85380/1/9789241505871_eng.pdf?ua=1. Last accessed April 2017
- Informe de la encuesta Europea de salud en España 2014. Available at:
 https://www.msssi.gob.es/estadEstudios/estadisticas/EncuestaEuropea/pdf/EESE14 inf.pdf.Last accessed:
 March 2018.
- 3. Impacto del consumo de tabaco sobre la mortalidad en Espana en el ano 2012. Eduardo Gutiérrez-Abejóna et al. Medicina Clinica 2015;145:520-5.

IV. Terms and Conditions

Please take note every Call for Grant Applications (CGA) released by Pfizer Independent Grants for Learning & Change (IGLC) is governed by specific terms and conditions. These terms and conditions can be reviewed here: http://www.pfizer.com/files/PfizerIGLC CGA TermsandConditions 2017Nov.pdf

Appendix: CGA Grant Submission Template

Grant Applications should be single-spaced using <u>Calibri 12-point font</u> and <u>1-inch margins</u>. Note there is a <u>15-page limit</u> exclusive of references. Please include the following:

- A. Title
- B. Organizational Detail: Describe the attributes of the institutions/organizations that will support and facilitate the execution of the project, the leadership of the proposed project, and the specific role of each partner in the proposed project.
- C. Goal: Briefly state the overall goal of the project.
- D. Objectives: List the objectives you plan to meet with your project, in terms of learning and expected outcomes.
- E. Assessment of Need: Include a quantitative baseline data summary, initial metrics, or a project starting point (please cite data on gap analyses or relevant patient-level data that informs the stated objectives) in your target area.
- F. Target Learner Audience: Describe the primary audience(s) targeted for this project. Indicate whom you believe will directly benefit from the project outcomes. Describe the overall population size as well as the size of your sample population.
- G. Project Design and Methods: Describe the planned project, the educational approach, and the way the planned methods address the established need.
- H. Innovation: Explain what measures you have taken to assure that this project idea is original and does not duplicate other projects or materials already developed. Describe how this project builds upon existing work, pilot projects, or ongoing projects developed either by your institution or other institutions related to this project.
- I. Outcomes Evaluation: In terms of the metrics used for the needs assessment, describe how you will determine if the gap was addressed for the target group. Identify the sources of data you anticipate using to make the determination. Describe how you expect to collect and analyze the data. Explain the method used to control for other factors outside this project (e.g., use of a control group or comparison with baseline data). Quantify the amount of change expected from this project in terms of your target audience. Describe how you will determine if the target audience was fully engaged in the project.
- J. Dissemination Plan: Describe how the project may have extended benefit beyond the grant. Will the teaching materials be made available to others to use? Will there be tools or resources that are made publicly available beyond the initial project. Describe how the project outcomes might be broadly disseminated.
- K. Timeline
- L. Additional Information: If there is any additional information you feel Pfizer should be aware of concerning the importance of this project, please summarize it in within the page limitations.
- M. References (outside the 15-page limit)
 - There is no designated format for references
- N. Budget (See template available in application)
 - While estimating your budget please keep the following items in mind:
 - Grants awarded by IGLC cannot be used to purchase therapeutic agents (prescription or nonprescription).
 - Pfizer maintains a company-wide, maximum allowed overhead rate of 28% for projects.
 - A separate Excel file should be uploaded. This does not count toward the page limit.
 - An example of the budget template can be found here: http://cybergrants.com/pfizer/docs/KnowledgeGapBudgetTemplate2015.xls
 - At the conclusion of your program, a reconciliation of expenses is required using the original budget file submitted.

Grant Applications should be single-spaced using <u>Calibri 12-point font</u> and <u>1-inch margins</u>. There is a <u>15-page limit</u> exclusive of references. If extensive, references may be included on 1-2 additional pages.